Securing the Global Pharmaceutical Supply Chain against the Threat of Counterfeit Drugs.

Published: Jun 1, 2014
The Scope and Prevention of Counterfeit Drugs

Many of recent counterfeit drug incidents — such as the 2012 Avastin incident where counterfeit versions were found in 19 American treatment centers — are sadly not isolated incidents. This white paper shares some insight into the history and geographical reach of counterfeit drugs, as well as prevention and countermeasures.

This white paper will discuss:

  • Growing trend and scope of counterfeit drugs
  • Impact to patients
  • Technological and regulatory countermeasures
  • Questions to consider with high-risk shipments
Ruediger Lomb
Ruediger Lomb, PhD
Vice President, Global Quality & Technical Compliance
AmerisourceBergen Specialty Group

As the vice president, global quality and technical compliance for the World Courier Group of Companies, as well as for Integrated Commercialization Solutions (ICS), Dr. Rüdiger Lomb oversees the quality program for both entities, ensuring facility and process compliance with all current and future GxP standards such as relevant FDA guidelines, the most recent EU Good Distribution Practices Guidelines and other relevant quality standards. Dr. Lomb is a licensed pharmacist and holds a Ph.D. in pharmaceutical biochemistry.